(Q42642774)

4 November 2017

0 references

Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma (English)

1 reference

4 November 2017

1 reference

Einarson TR

1

1 reference

4 November 2017

Kulin NA

series ordinal

2

1 reference

4 November 2017

Tingey D

series ordinal

3

1 reference

4 November 2017

Iskedjian M

series ordinal

4

1 reference

4 November 2017

publication date

1 December 2000

1 reference

4 November 2017

published in

Clinical Therapeutics

1 reference

4 November 2017

volume

22

1 reference

4 November 2017

issue

12

1 reference

4 November 2017

page(s)

1502-1515

1 reference

4 November 2017

cites work

Treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Why do some people go blind from glaucoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Screening for glaucoma. Why is the disease underdetected?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Prevalence of glaucoma in Ponza, Italy: a comparison with other studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

The age distribution of primary open angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Prevalence of glaucoma and distribution of intraocular pressure in a population. The Casteldaccia Eye Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Glaucoma risk factors observed in the Baltimore Eye Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Comparison of the ocular beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

The Ocular Hypertension Treatment Study: design and baseline description of the participants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Longterm visual field follow-up of glaucoma patients treated with beta-blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

1 reference

7 January 2021

The role of brimonidine in the treatment of open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Betaxolol eye drops. A clinical trial of safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Pharmacological advances in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Corneal toxicity associated with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Latanoprost and herpes simplex keratitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

A method for meta-analysis of epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

The Combination of Estimates from Different Experiments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Rules of evidence and clinical recommendations on the use of antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

Cost considerations of medical therapy for glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983048-9

7 January 2021

10.1016/S0149-2918(00)83048-9

Identifiers

DOI

1 reference

4 November 2017

1 reference